🇺🇸 RiaSTAP in United States

112 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 112

Most-reported reactions

1. No Adverse Event — 33 reports (29.46%)
2. Off Label Use — 23 reports (20.54%)
3. Product Use In Unapproved Indication — 10 reports (8.93%)
4. Pyrexia — 9 reports (8.04%)
5. Dyspnoea — 8 reports (7.14%)
6. Drug Ineffective — 7 reports (6.25%)
7. Cerebrovascular Accident — 6 reports (5.36%)
8. Hypotension — 6 reports (5.36%)
9. Haemorrhage — 5 reports (4.46%)
10. Pulmonary Oedema — 5 reports (4.46%)

Source database →

Frequently asked questions

Is RiaSTAP approved in United States?

RiaSTAP does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for RiaSTAP in United States?

Weill Medical College of Cornell University is the originator. The local marketing authorisation holder may differ — check the official source linked above.